News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN)'s Brilique is First Drug to Gain Post-AMNOG Decision in Germany


12/19/2011 8:44:14 AM

Germany's Federal Joint Committee (G-BA) has delivered a positive opinion for AstraZeneca's antiplatelet therapy Brilique, the first drug to be assessed under new pricing assessment laws that came into effect on January 1, 2011. Overall, the G-BA came down in favour of Brilique (ticagrelor) as a treatment for patients with acute coronary syndromes, allowing AstraZeneca to start pricing negotiations with the German health insurance system in the New Year. "The G-BA's final assessment acknowledges the additional benefit that Brilique provides approximately 80 per cent of the ACS patient population in Germany," said AstraZeneca in a statement.

Read at News Release
Read at News Release
Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES